Becton Dickinson Vitals Drop: Analysts 'Have Been Wrong' On This Med Tech Stock For Years

benzinga.com/general/health-care/25/05/45179007/becton-dickinson-vitals-drop-analysts-have-been-wrong-on-this-med-tech-stock-for-years

Becton Dickinson, and Company (NYSE:BDX) lowered its fiscal year 2025 guidance and provided an estimated tariff impact on Thursday.
The medical device company reported adjusted earnings per share of $3.35, up from $3.17 a year ago. It beat the consensus of $3.28.
The company reported…

This story appeared on benzinga.com, 2025-05-02 20:33:42.